Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.68 |
| ▸ | GABRD | O14764 | 2/20 | 0.68 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.68 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.68 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.68 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.68 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.68 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.68 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.68 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.68 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.68 |
| ▸ | GABRE | P78334 | 2/20 | 0.68 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.68 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.68 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.68 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | CCNE2 | O96020 | 11/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.55 |
| ▸ | CDK2 | P24941 | 11/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575850 | 1.00 | GABRP (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11678300 | 0.89 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11757670 | 0.88 | GABRA1 (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11684251 | 0.87 | GABRA1 (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11683712 | 0.87 | GABRA1 (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11460474 | 0.85 | LMNA (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Clonazepam SCHEMBL13747803 | 0.81 | GABRA1 (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Clonazepam SCHEMBL29743048 | 0.81 | GABRA1 (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Clonazepam SCHEMBL38899 | 0.81 | GABRA1 (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Clonazepam SCHEMBL29369721 | 0.81 | GABRA1 (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110072521-A | Pharmaceutical combination comprising a T-type calcium channel blocker | 爱杜西亚药品有限公司 | 2019-07-30 | — | — | CN | claimed |
| CN-110072521-A | Pharmaceutical combination comprising a T-type calcium channel blocker | 爱杜西亚药品有限公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-108992449-A | Application of the Clonazepam in preparation treatment adolescent depression disease drug | 南方医科大学 | 2018-12-14 | — | — | CN | disclosed |
| EP-2131830-B1 | PHARMACEUTICAL FORM WITH IMPEDED ABUSE | GRUENENTHAL GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-3151819-A1 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | Acura Pharmaceuticals, Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015191501-A1 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | ACURA PHARMACEUTICALS, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| CN-101594868-B | Pharmaceutical composition with antipsychotic, antidepressant or antiepileptic activity and reduced side effects | GENE RES LAB INC US N | 2012-12-12 | — | — | CN | disclosed |
| EP-2131830-A2 | PHARMACEUTICAL FORM WITH IMPEDED ABUSE | Grünenthal GmbH (DE) | 2009-12-16 | — | — | EP | disclosed |
| CN-101594868-A | Pharmaceutical composition with antipsychotic, antidepressant or antiepileptic activity and reduced side effects | N GENE RES LAB INC (US) | 2009-12-02 | — | — | CN | disclosed |
| WO-2008107149-A2 | PHARMACEUTICAL FORM WITH IMPEDED ABUSE | Grünenthal GmbH (DE) | 2008-09-12 | — | — | WO | disclosed |
| CN-100415222-C | Methods of using and compositions comprising dopamine reuptake inhibitors | SEPRACOR INC (US) | 2008-09-03 | — | — | CN | disclosed |
| EP-1765298-A1 | METHOD FOR PRODUCING A SOLID DOSAGE FORM, WHICH IS SAFEGUARDED AGAINST ABUSE, WHILE USING A PLANETARY GEAR EXTRUDER | GRUENENTHAL GMBH (DE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006058249-A9 | METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF ORALLY ADMINISTERED PHARMACEUTICAL PRODUCTS | ACURA PHARMACEUTICALS INC (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006002883-A1 | METHOD FOR PRODUCING A SOLID DOSAGE FORM, WHICH IS SAFEGUARDED AGAINST ABUSE, WHILE USING A PLANETARY GEAR EXTRUDER | Grünenthal GmbH (DE) | 2006-01-12 | — | — | WO | disclosed |
| US-4044003-A | Process for preparing 1,4-benzodiazepines | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-08-23 | — | — | US | disclosed |